Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Saved in:
| Title: | Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. |
|---|---|
| Authors: | Boutry, Céline1, Hastie, Andrew2 andrew.x.hastie@gsk.com, Diez-Domingo, Javier3, Tinoco, Juan Carlos4, Yu, Chong-Jen5, Andrews, Charles6, Beytout, Jean7, Caso, Covadonga8, Cheng, Huey-Shinn9, Cheong, Hee Jin10, Choo, Eun Ju11, Curiac, Dan12, Paolo, Emmanuel Di13, Dionne, Marc14, Eckermann, Tamara15, Esen, Meral16, Ferguson, Murdo17, Ghesquiere, Wayne18, Hwang, Shinn-Jang19,20, Avelino-Silva, Thiago Junqueira21 |
| Source: | Clinical Infectious Diseases. 4/15/2022, Vol. 74 Issue 8, p1459-1467. 9p. |
| Database: | Environment Complete |
Be the first to leave a comment!
